Trials / Completed
CompletedNCT02415842
A Laboratory Evaluation of the Humoral Immune Response in Adults and Children to the H1 Hemagglutinin (HA) Stalk Domain and Other Influenza A Virus Protein Epitopes, After Administration of GlaxoSmithKline (GSK) Biologicals' Pandemic Influenza Vaccines
An Exploratory, Retrospective Laboratory Evaluation of the Humoral Immune Response in Adults and Children to the H1 HA Stalk Domain and Other Influenza A Virus Protein Epitopes, After Administration of GSK Biologicals' Pandemic Influenza Vaccines
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 414 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 6 Months – 64 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this exploratory, retrospective laboratory study is to assess the humoral immune response to H1 hemagglutinin stalk domain and other influenza A virus protein epitopes following administration, in adults and children, of GSK Biologicals' adjuvanted and unadjuvanted pandemic influenza vaccines, using archived serum samples from previously completed clinical trials.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Serum samples | The archived sera samples collected in previously completed pandemic influenza vaccine clinical trials (H1N1, H5N1, and H9N2 pandemic vaccines in adult trials and H5N1 pandemic vaccine in a pediatric trial) will be tested in this study. |
Timeline
- Start date
- 2015-10-26
- Primary completion
- 2018-02-16
- Completion
- 2018-02-16
- First posted
- 2015-04-14
- Last updated
- 2019-07-23
- Results posted
- 2019-06-28
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02415842. Inclusion in this directory is not an endorsement.